AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Trading Resumes in Canadian Investment Regulatory Organization - Cardiol Therapeutics Inc.
ByAinvest
Monday, Oct 20, 2025 8:21 am ET1min read
Trading resumes in Cardiol Therapeutics Inc. (CRDL) on the Toronto Stock Exchange at 8:00 AM after a temporary suspension. The Canadian Investment Regulatory Organization (CIRO) halted trading to ensure a fair and orderly market. CIRO oversees investment dealers and trading activity on debt and equity marketplaces in Canada.
Trading in Cardiol Therapeutics Inc. (CRDL) resumed on the Toronto Stock Exchange at 8:00 AM following a temporary suspension imposed by the Canadian Investment Regulatory Organization (CIRO). The suspension was initiated to ensure a fair and orderly market, reflecting CIRO's oversight of investment dealers and trading activities on Canadian debt and equity marketplaces.The suspension comes amidst significant developments for Cardiol Therapeutics. The company recently secured US$11 million in financing through a private placement offering, which will support its operations into the third quarter of 2027, according to a .
CardiolRx™, which has been granted Orphan Drug Designation by the FDA for the treatment of pericarditis, has shown promising results in reducing left ventricular (LV) mass and preventing heart failure. The ARCHER trial, a Phase II study in acute myocarditis, demonstrated significant reductions in LV mass, a key indicator of structural and remodeling improvement. These findings were presented at a cardiology conference in November 2025, Reuters reported.
The MAVERIC trial, a pivotal Phase III study for recurrent pericarditis, is also progressing, with several prominent centers across the U.S. now enrolling patients. This trial is fully funded through to a planned New Drug Application submission with the FDA, Reuters reported.
The temporary suspension of trading in Cardiol Therapeutics underscores the importance of regulatory oversight in maintaining market integrity. As the company continues to advance its innovative therapies for heart disease, investors will be closely monitoring its progress and the impact of its clinical trials on the broader market.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet